Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | C1R | P00736 | 7/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | F2 | P00734 | 4/20 | 0.61 |
| ▸ | PLG | P00747 | 1/20 | 0.61 |
| ▸ | KLK1 | P06870 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.61 |
| ▸ | C1S | P09871 | 1/20 | 0.61 |
| ▸ | ELANE | P08246 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KLK3 | P07288 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28859792 | 0.86 | C1R (0.61) | ATML3MBTL1C1RKMT2AF2 | |
| SCHEMBL1478089 | 0.84 | C1R (0.59) | ATML3MBTL1C1RKMT2AF2 | |
| SCHEMBL9475884 | 0.83 | C1R (0.78) | ATML3MBTL1C1RKMT2AF2 | |
| SCHEMBL29791056 | 0.83 | C1R (0.78) | ATML3MBTL1C1RKMT2AF2 | |
| SCHEMBL18963257 | 0.81 | C1R (0.76) | ATML3MBTL1C1RKMT2AF2 | |
| SCHEMBL9475739 | 0.81 | C1R (0.76) | ATML3MBTL1C1RKMT2AF2 | |
| SCHEMBL10749958 | 0.81 | NPC1 (0.51) | ATMKMT2AMEN1MAPTNPC1 | |
| SCHEMBL3710461 | 0.81 | ATM (0.62) | ATML3MBTL1C1RKMT2AF2 | |
| SCHEMBL2537274 | 0.80 | ELANE (0.73) | ATML3MBTL1C1RKMT2AF2 | |
| SCHEMBL30914649 | 0.80 | ELANE (0.73) | ATML3MBTL1C1RKMT2AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6180625-B1 | MODULATING AND NORMALIZING AN IMPAIRED HAEMOSTATIC BALANCE IN A MAMMAL, WHICH METHOD COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF NOVEL BENZOXAZIN DERIVATIVES; ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 2001-01-30 | — | — | US | claimed |
| CN-100518740-C | Pharmaceutical use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2009-07-29 | — | — | CN | disclosed |
| CN-101152185-A | Use of heterocyclic compounds as scce inhibitors | AREXIS AB (SE) | 2008-04-02 | — | — | CN | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| CN-1802160-A | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2006-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | ATM 3829/4885L3MBTL1 4230/4885C1R 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.